title: [Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].
abstract: In this review article, we describe the unrecognized roles of glutamate and glutamate receptors in malignant glioma biology. The neurotransmitter glutamate released from malignant glioma cells in the extracellular matrix is responsible for seizure induction and at higher concentration neuronal cell death. This neuronal cell death will create vacated place for tumor growth. Glutamate also stimulates the growth and the migration of glial tumor cells by means of the activation of glutamate receptors on glioma cells in a paracrine and autocrine manner. The multitude of effects of glutamate in glioma biology supports the rationale for pharmacological targeting of glutamate receptors and transporters in the adjuvant treatment of malignant gliomas in neurology and neuro-oncology. Using the website www.clinicaltrials.gov/ as a reference - a service developed by the National Library of Medicine for the National Health Institute in USA - we have evoked the few clinical trials completed and currently ongoing with therapies targeting the glutamate receptors.
authors.affiliation: Service de neurologie, Epicura, 7800 Ath, Belgique.
authors.forename: Serge
authors.initials: S
authors.lastname: Blecic
authors.forename: Michal
authors.initials: M
authors.lastname: Rynkowski
authors.forename: Olivier
authors.initials: O
authors.lastname: De Witte
authors.forename: Florence
authors.initials: F
authors.lastname: Lefranc
mesh_terms: D001569:Benzodiazepines / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016923:Cell Death; D002465:Cell Movement / Q000502:physiology; D049109:Cell Proliferation; D016291:Dizocilpine Maleate / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D005910:Glioma / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018698:Glutamic Acid / Q000502:physiology*; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009457:Neuroglia / Q000502:physiology; D009474:Neurons / Q000502:physiology; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors; D017470:Receptors, Glutamate / Q000502:physiology*; D012640:Seizures / Q000188:drug therapy / Q000209:etiology; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018091:Receptors, AMPA; D017470:Receptors, Glutamate; D001569:Benzodiazepines; D018698:Glutamic Acid; D012460:Sulfasalazine; D016291:Dizocilpine Maleate; C085266:talampanel; D008559:Memantine
keywords: epilepsia; glutamate; invasion; malignant gliomas; migration; proliferation; sulfasalazine